Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

iPad

- PMLiVE

First UK proton beam therapy trial launches for certain breast cancer patients

The trial will assess the therapy in patients at risk of heart problems after standard radiotherapy

- PMLiVE

ICR and University of Cambridge reveal new prostate cancer prediction tool

The new study describing the model is published in the Journal of Clinical Oncology

- PMLiVE

Lab-grown red blood cells used for human transfusions in world-first clinical trial

Manufactured blood cells could revolutionise treatments for people with blood disorders

- PMLiVE

New study finds signs of dementia could be detected nine years before diagnosis

Impairment was observed in several areas across a range of dementia-related diseases

- PMLiVE

Empowering adolescents to manage emotional and mental health issues

1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...

Create Health

- PMLiVE

Cancer Research UK scientists announce ‘breakthrough’ in understanding of metastasis

The team found that cancer cells ‘exploit’ the body’s tissue repair process to spread cells

- PMLiVE

University of Cambridge launches Early Cancer Institute for complex cancers

It is the first UK institute dedicated to identifying and researching early cancers

- PMLiVE

Cambridge University develops DNA test for secondary infections in COVID-19 patients

Test can identify cases of ‘ventilator-associated pneumonia’

- PMLiVE

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Target action date for FDA decision is due on 15 November

- PMLiVE

Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug

- PMLiVE

Intra-Cellular soars on FDA approval of schizophrenia drug

Shares rocketed following the announcement

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links